Vascular wall proteoglycan synthesis and structure as a target for the prevention of atherosclerosis

Area of Science:

• Vascular Biology
• Biochemistry
• Cardiovascular Disease Research

Background:

• Atherosclerosis is a primary cause of cardiovascular disease and premature death.
• Current therapies targeting risk factors have limited efficacy (≤30%).
• Vascular wall-directed therapies are needed, focusing on inflammation, oxidation, endothelial dysfunction, and lipid retention.

Purpose of the Study:

• To explore the role of vascular matrix proteoglycans in low-density lipoprotein (LDL) binding.
• To investigate the regulation of proteoglycan structure by vasoactive substances and novel signaling pathways.
• To identify modifying proteoglycan synthesis and structure as a potential therapeutic target for atherosclerosis.

Main Methods:

• Review of emerging data on proteoglycan structure-function relationships in atherosclerosis.
• Analysis of glycosaminoglycan (GAG) chain length and sulfation patterns in LDL binding.
• Examination of regulatory mechanisms involving vasoactive substances and signaling pathways, including platelet-derived growth factor (PDGF).

Main Results:

• Proteoglycan structural features, specifically GAG chain length and sulfation, dictate LDL binding.
• Vasoactive substances can regulate these structural properties through potentially novel signaling pathways.
• Platelet-derived growth factor (PDGF)-stimulated GAG elongation is not inhibited by genistein, suggesting a new pathway.

Conclusions:

• Targeting proteoglycan synthesis and structure is a promising strategy to prevent LDL binding and entrapment in the vessel wall.
• This approach may offer a complementary therapy to reduce the development and progression of atherosclerosis.
• Understanding novel signaling pathways regulating proteoglycans is crucial for developing effective vascular wall-directed treatments.